Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy

Michelle E. LeBlanc, Weiwen Wang, Xiuping Chen, Nora B. Caberoy, Feiye Guo, Chen Shen, Yanli Ji, Hong Tian, Hui Wang, Rui Chen, Wei Li

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Diabetic retinopathy (DR) is a leading cause of vision loss with retinal vascular leakage and/or neovascularization. Current antiangiogenic therapy against vascular endothelial growth factor (VEGF) has limited efficacy. In this study, we applied a new technology of comparative ligandomics to diabetic and control mice for the differential mapping of disease-related endothelial ligands. Secretogranin III (Scg3) was discovered as a novel disease-associated ligand with selective binding and angiogenic activity in diabetic but not healthy vessels. In contrast, VEGF bound to and induced angiogenesis in both diabetic and normal vasculature. Scg3 and VEGF signal through distinct receptor pathways. Importantly, Scg3-neutralizing antibodies alleviated retinal vascular leakage in diabetic mice with high efficacy. Furthermore, anti-Scg3 prevented retinal neovascularization in oxygen-induced retinopathy mice, a surrogate model for retinopathy of prematurity (ROP). ROP is the most common cause of vision impairment in children, with no approved drug therapy. These results suggest that Scg3 is a promising target for novel antiangiogenic therapy of DR and ROP.

Original languageEnglish (US)
Pages (from-to)1029-1047
Number of pages19
JournalJournal of Experimental Medicine
Issue number4
StatePublished - Apr 1 2017

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy'. Together they form a unique fingerprint.

Cite this